Close

Anti-EXOC8 Q656P T cell receptor (MEL218), pCDTCR1 (TCR-YC0384)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-EXOC8 Q656P T cell receptor (TCR) is constructed for the engineering of T cell to target EXOC8 Q656P (IILVAVPHV) restricted by HLA-A*02:01. The T cells are genetically modified through transduction with a lentiviral vector expressing EXOC8 Q656P-specific T cell receptor.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • EXOC8 Q656P
  • Epitope
  • IILVAVPHV
  • Format
  • Non-Modified TCR
  • Allele
  • HLA-A*02:01
  • Vector Name
  • pCDTCR1
  • Vector Length
  • ~ 8 kb
  • Vector Type
  • Lentiviral vector
  • TCR Clone
  • MEL218
  • Host Species
  • Human

Target

  • Introduction
  • TMEM48 F169L, SEC24A P469L, and EXOC8 Q656P represent dominant antigens as T cell immunity was detected prior to vaccination (naturally occurring) and these neoantigens are processed and presented from endogenously expressed protein. TKT R438W, CDKN2A E153K, AKAP13 Q285K and PABPC1 R520Q are characterized as subdominant antigens as T cell immunity required peptide vaccination and these neoantigens are processed and presented from endogenously expressed protein.

Customer Reviews and Q&As

There are currently no customer reviews or questions for Human anti-EXOC8 Q656P T cell receptor (MEL218), pCDTCR1 (TCR-YC0384). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.